Featured Publications
Emerging Immunohistochemical Biomarkers for Myeloid Neoplasms.
Verma A, Xu ML. Emerging Immunohistochemical Biomarkers for Myeloid Neoplasms. Archives Of Pathology & Laboratory Medicine 2022, 147: 403-412. PMID: 35533352, DOI: 10.5858/arpa.2021-0558-ra.Peer-Reviewed Original ResearchConceptsMyeloid neoplasmsImmunohistochemical biomarkersImmunohistochemical markersManagement of patientsNovel immunohistochemical markerPosttreatment biopsiesImmunohistochemical toolsDisease progressionCorrect diagnosisClinical scenariosNeoplasmsPatient careLiterature searchRelevant biomarkersBiomarkersImmunohistochemistryMolecular biomarkersScientific literature searchMarkersArchival samplesOriginal articlesMolecular eraCurrent eraPatientsBiopsy
2022
Liquid Biopsy-Based Next-Generation Sequencing Is an Alternative to Tissue Molecular Profiling of Lymphoid, Plasma-Cell, and Myeloid Neoplasms
Mata D, Lee J, Decker B, Shanmugam V, Marcus C, Tukachinsky H, Schrock A, Patel N, Ross J, Oxnard G, Vergilio J, Mirza K, Xu M, Benhamida J. Liquid Biopsy-Based Next-Generation Sequencing Is an Alternative to Tissue Molecular Profiling of Lymphoid, Plasma-Cell, and Myeloid Neoplasms. Blood 2022, 140: 1205-1207. DOI: 10.1182/blood-2022-159106.Peer-Reviewed Original ResearchLiquid biopsy (LB)-based comprehensive genomic profiling (CGP) of circulating tumor DNA (ctDNA) for the evaluation of patients with myeloid neoplasms.
Mata D, Xu M, Shanmugam V, Tukachinsky H, Schrock A, Ross J, Williams E, Montesion M, Decker B, Vergilio J, Oxnard G, Benhamida J. Liquid biopsy (LB)-based comprehensive genomic profiling (CGP) of circulating tumor DNA (ctDNA) for the evaluation of patients with myeloid neoplasms. Journal Of Clinical Oncology 2022, 40: e19064-e19064. DOI: 10.1200/jco.2022.40.16_suppl.e19064.Peer-Reviewed Original ResearchComprehensive genomic profilingAcute myeloid leukemiaMyelodysplastic syndromeHistiocytic neoplasmsMyeloproliferative neoplasmsMyeloid neoplasiaAML casesMinimal residual disease testingPathogenic alterationsHybrid-capture next-generation sequencingSolid tumor diagnosisEvaluation of patientsRoutine clinical careRelevant genomic alterationsMonitoring of patientsUnique patient samplesRetrospective studyMyeloid leukemiaMyeloid neoplasmsClinical carePatientsKRAS G12AInsufficient tumorDisease testingPathway alterationsDNMT3A R882 Mutations Confer Unique Clinicopathologic Features in MDS Including a High Risk of AML Transformation
Jawad M, Afkhami M, Ding Y, Zhang X, Li P, Young K, Xu ML, Cui W, Zhao Y, Halene S, Al-Kali A, Viswanatha D, Chen D, He R, Zheng G. DNMT3A R882 Mutations Confer Unique Clinicopathologic Features in MDS Including a High Risk of AML Transformation. Frontiers In Oncology 2022, 12: 849376. PMID: 35296003, PMCID: PMC8918526, DOI: 10.3389/fonc.2022.849376.Peer-Reviewed Original ResearchWorse progression-free survivalProgression-free survivalMyelodysplastic syndromeAML transformationMyeloid neoplasmsMDS casesHigh riskR882 mutationsClonal hematopoiesisIndependent risk factorUnique clinicopathologic featuresTertiary medical institutionsDifferent treatment approachesUnique clinicopathologicExcess blastsSevere leukopeniaClinicopathologic featuresMutant patientsRisk factorsLarge cohortTherapeutic implicationsTreatment approachesClinical implicationsClinical-genomic databaseNeoplasms
2019
Clinicopathologic and genetic characterization of nonacute NPM1-mutated myeloid neoplasms
Patel SS, Ho C, Ptashkin RN, Sadigh S, Bagg A, Geyer JT, Xu ML, Prebet T, Mason EF, Seegmiller AC, Morgan EA, Steensma DP, Winer ES, Wong WJ, Hasserjian RP, Weinberg OK. Clinicopathologic and genetic characterization of nonacute NPM1-mutated myeloid neoplasms. Blood Advances 2019, 3: 1540-1545. PMID: 31085507, PMCID: PMC6517660, DOI: 10.1182/bloodadvances.2019000090.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overDNA (Cytosine-5-)-MethyltransferasesDNA Methyltransferase 3AFemaleHumansMaleMiddle AgedMutationMyelodysplastic SyndromesNuclear ProteinsNucleophosminPrognosisProportional Hazards ModelsProtein Tyrosine Phosphatase, Non-Receptor Type 11Survival RateTumor Suppressor Protein p53ConceptsMyelodysplastic syndromeMyeloid neoplasmsDe novo acute myeloid leukemia (AML) patientsNovo acute myeloid leukemia patientsAcute myeloid leukemia patientsBone marrow blastsAggressive clinical courseStem cell transplantLimited case seriesShorter overall survivalMyeloid leukemia patientsIntensive therapeutic regimensTotal mutation countsMarrow blastsOverall survivalClinical courseCase seriesCell transplantMultivariable analysisTherapeutic regimensLeukemia patientsLarge cohortYounger agePatientsNormal karyotype